← Back to screener

Vaxcyte, Inc. PCVX

Rank #2225 · Nasdaq · $9.0B market cap
Audited by Deloitte & Touche LLP, no going-concern flag in the latest filing.
Score
28.4
P/E
-22.3
P/B
9.39
ROE
-42.2%
Op. Margin
–%
Debt Ratio
22%

Health Check — percentile rank within this universe, based on the latest annual filing

Valuation ★☆☆☆☆
Weak

P/E -22.3x, P/B 9.39x. Ranks in the top 79% of the universe.

Profitability ★☆☆☆☆
Poor

ROE -42.2%. Ranks in the top 87% of the universe.

Safety ★★★★☆
Excellent

Debt ratio 22%. Ranks in the top 14% of the universe. Under 100% is generally considered a safe level.

Growth –
No data

Not enough historical filings to compute year-over-year growth yet.

Safety is the relative strength · Valuation is the relative weakness (relative to this universe).

Financials annual, from SEC 10-K filings

FYRevenueOp. IncomeNet IncomeEquityOp. Margin%Debt%
2020–$-0.0B$-0.0B$-0.0B–-40
2021–$-0.1B$-0.1B$-0.1B–-81
2022–$-0.1B$-0.1B$-0.1B–-38
2023–$-0.1B$-0.1B$0.3B–15
2024–$-0.2B$-0.2B$0.3B–59
2025–$-0.5B$-0.4B$1.0B–22

← See the full screener